Vogt Optoelectronics: Aerospace CPI products have not yet achieved mass production. Microfluidic biological chips do not involve chip design and manufacturing.

Wog Optoelectronics announced that the company's aerospace CPI products have not yet achieved mass production, and the aforementioned on-orbit applications only involve the flexible solar wings of individual satellites, with a small order amount. Currently, the orders signed by the company with related customers are in the product testing and validation stage, accounting for less than 0.1% of the company's revenue in 2025, and will not have a significant impact on the company's business performance. In addition, the company's "microfluidic biological chip" business mainly uses the company's glass-based TGV and precision processing technology to provide downstream customers with the glass substrates or basic structural components required for biological chips, without involving chip design and manufacturing. In 2025, the company's cumulative sales revenue from microfluidics-related products in the field of biomedicine is $107,900, accounting for a very small proportion of the company's overall revenue.